Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494946 | 0.92 | AKR1B1 (0.33) | AKR1B1PIK3CBHSP90AA1HTR2AGRM2 | |
| SCHEMBL4494915 | 0.92 | AKR1B1 (0.33) | AKR1B1PIK3CBHSP90AA1MDM2HTR2A | |
| SCHEMBL4482041 | 0.89 | AKR1B1 (0.39) | AKR1B1MAPK1 | |
| SCHEMBL4479511 | 0.89 | AKR1B1 (0.36) | AKR1B1PIK3CBHTR2AGRM2PIK3CA | |
| SCHEMBL31060990 | 0.89 | AKR1B1 (0.36) | AKR1B1PIK3CBHTR2AGRM2PIK3CA | |
| SCHEMBL4489034 | 0.89 | AKR1B1 (0.38) | AKR1B1HSP90AA1HTR2AGRM2PIK3CA | |
| SCHEMBL4481021 | 0.88 | AKR1B1 (0.35) | AKR1B1PIK3CBHSP90AA1HTR2AGRM2 | |
| SCHEMBL4488414 | 0.88 | AKR1B1 (0.35) | AKR1B1PIK3CBHTR2AGRM2PIK3CA | |
| SCHEMBL4483837 | 0.87 | AKR1B1 (0.36) | AKR1B1PIK3CBHTR2AGRM2PIK3CA | |
| SCHEMBL4490977 | 0.86 | AKR1B1 (0.42) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | claimed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20140243348-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013028297-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2010017056-A1 | ORALLY ADMINISTERED SOLID FORMULATIONS CONTAINING A HYDROPHOBIC DRUG AND TPGS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006107478-A2 | CRYSTALLINE SODIUM SALT OF AN HIV INTEGRASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243348-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | EBNA1BP2, RPL17, TK2 | AKR1B1 2717/4885PIK3CB 277/4885HSP90AA1 934/4885 |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | AKR1B1 2301/4885PIK3CB 2320/4885HSP90AA1 1812/4885 |
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | AKR1B1 2248/4885PIK3CB 259/4885HSP90AA1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.